Petricoul, Olivier
Nazarian, Arman
Schuehly, Uwe
Schramm, Ursula
David, Olivier J.
Laurent, Didier
Praestgaard, Jens
Roubenoff, Ronenn
Papanicolaou, Dimitris A.
Rooks, Daniel
Funding for this research was provided by:
Novartis Institutes for BioMedical Research, Basel, Switzerland
Article History
Accepted: 1 November 2022
First Online: 17 December 2022
Declarations
:
: All authors participated in the study design and implementation and/or conduct of the study. All authors read and approved the final manuscript.
: This study was funded by Novartis Institutes for BioMedical Research, Basel, Switzerland
: Olivier Petricoul, Arman Nazarian, Uwe Schuehly, Ursula Schramm, Olivier J. David, Didier Laurent, Jens Praestgaard, Ronenn Roubenoff, Dimitris A. Papanicolaou, and Daniel Rooks are employees of Novartis and, as such, may be eligible for Novartis stock and stock options.
: Data that support the findings of this study may be available upon reasonable request. Inquiries should be sent to info@versanisbio.com
: The study was designed by the Novartis Institutes of BioMedical Research (NIBR) and executed in collaboration with external principal investigators and their study sites. The data were analyzed by an independent contractor, and the NIBR study team was responsible for data interpretation.
: The study was conducted according to the ethical principles of the Declaration of Helsinki. The study protocol was reviewed by the Institutional Review Board for each center.
: Written informed consent was obtained from each participant before conducting any study-specific procedures.
: Not applicable.
: Not applicable.